Royalty Pharma plc Class A Ordinary Shares (RPRX) is a publicly traded Healthcare sector company. As of May 21, 2026, RPRX trades at $53.06 with a market cap of $23.08B and a P/E ratio of 27.85. RPRX moved +1.21% today. Year to date, RPRX is +33.82%; over the trailing twelve months it is +60.35%. Its 52-week range spans $24.05 to $53.47. Analyst consensus is strong buy with an average price target of $59.43. Rallies surfaces RPRX's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
RPRX financials on Rallies include revenue, net income, EPS, valuation metrics, market cap, price history, and balance sheet context. RPRX recently traded at $53.06. Market cap is $23.08B. P/E ratio is 27.85. Revenue is $2.44B.
| Metric | Value |
|---|---|
| Price | $53.06 |
| Market Cap | $23.08B |
| P/E Ratio | 27.85 |
| EPS | $1.91 |
| Dividend Yield | 0.23% |
| 52-Week High | $53.47 |
| 52-Week Low | $24.05 |
| Volume | 4.70K |
| Avg Volume | 0 |
| Revenue (TTM) | $2.44B |
| Net Income | $1.36B |
| Gross Margin | 0.00% |
| Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $2.38B | $1.32B | $1.79 |
| 2023 | $2.35B | $1.70B | $2.54 |
| 2022 | $2.24B | $230.06M | $0.10 |
| 2021 | $2.29B | $1.24B | $1.49 |
7 analysts cover RPRX: 0 strong buy, 7 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $59.43.